X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Aventis Pharma with ASTRAZENECA PHARMA - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SANOFI INDIA vs ASTRAZENECA PHARMA - Comparison Results

SANOFI INDIA    Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

ASTRAZENECA PHARMA 
   Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SANOFI INDIA ASTRAZENECA PHARMA SANOFI INDIA/
ASTRAZENECA PHARMA
 
P/E (TTM) x 34.3 105.3 32.6% View Chart
P/BV x 6.5 15.0 43.6% View Chart
Dividend Yield % 1.4 0.0 -  

Financials

 SANOFI INDIA   ASTRAZENECA PHARMA
EQUITY SHARE DATA
    SANOFI INDIA
Dec-16
ASTRAZENECA PHARMA
Mar-14
SANOFI INDIA/
ASTRAZENECA PHARMA
5-Yr Chart
Click to enlarge
High Rs4,5601,285 354.9%   
Low Rs4,400634 694.0%   
Sales per share (Unadj.) Rs1,028.5189.6 542.5%  
Earnings per share (Unadj.) Rs129.0-0.2 -63,341.0%  
Cash flow per share (Unadj.) Rs186.03.8 4,837.6%  
Dividends per share (Unadj.) Rs68.000-  
Dividend yield (eoy) %1.50-  
Book value per share (Unadj.) Rs753.668.6 1,097.9%  
Shares outstanding (eoy) m23.0325.00 92.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.45.1 86.1%   
Avg P/E ratio x34.7-4,712.7 -0.7%  
P/CF ratio (eoy) x24.1249.6 9.7%  
Price / Book Value ratio x5.914.0 42.5%  
Dividend payout %52.70-   
Avg Mkt Cap Rs m103,17423,988 430.1%   
No. of employees `0003.61.6 232.4%   
Total wages/salary Rs m3,5921,605 223.9%   
Avg. sales/employee Rs Th6,537.73,040.2 215.0%   
Avg. wages/employee Rs Th991.41,029.2 96.3%   
Avg. net profit/employee Rs Th819.8-3.3 -25,108.3%   
INCOME DATA
Net Sales Rs m23,6864,740 499.7%  
Other income Rs m70892 768.7%   
Total revenues Rs m24,3944,832 504.9%   
Gross profit Rs m5,281-130 -4,068.6%  
Depreciation Rs m1,313101 1,297.4%   
Interest Rs m150-   
Profit before tax Rs m4,661-139 -3,355.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0139 0.0%   
Tax Rs m1,6915 33,222.0%   
Profit after tax Rs m2,970-5 -58,349.7%  
Gross profit margin %22.3-2.7 -814.1%  
Effective tax rate %36.3-3.7 -990.0%   
Net profit margin %12.5-0.1 -11,676.1%  
BALANCE SHEET DATA
Current assets Rs m15,6732,726 574.9%   
Current liabilities Rs m6,6782,435 274.3%   
Net working cap to sales %38.06.1 617.7%  
Current ratio x2.31.1 209.6%  
Inventory Days Days7674 103.0%  
Debtors Days Days2241 54.7%  
Net fixed assets Rs m8,0981,035 782.2%   
Share capital Rs m23050 460.6%   
"Free" reserves Rs m17,088942 1,813.3%   
Net worth Rs m17,3561,716 1,011.4%   
Long term debt Rs m00-   
Total assets Rs m25,4004,156 611.2%  
Interest coverage x311.7NM-  
Debt to equity ratio x00-  
Sales to assets ratio x0.91.1 81.8%   
Return on assets %11.8-0.1 -9,595.5%  
Return on equity %17.1-0.3 -5,769.1%  
Return on capital %26.90-  
Exports to sales %24.55.7 429.6%   
Imports to sales %28.06.5 432.9%   
Exports (fob) Rs m5,801270 2,146.9%   
Imports (cif) Rs m6,627306 2,163.6%   
Fx inflow Rs m7,145375 1,907.4%   
Fx outflow Rs m6,846470 1,456.1%   
Net fx Rs m299-96 -312.9%   
CASH FLOW
From Operations Rs m3,226-8 -39,827.2%  
From Investments Rs m-1,555-146 1,067.3%  
From Financial Activity Rs m-1,818862 -210.9%  
Net Cashflow Rs m-147709 -20.7%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 60.4 75.0 80.5%  
Indian inst/Mut Fund % 14.4 0.3 4,800.0%  
FIIs % 14.6 15.7 93.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 9.1 115.4%  
Shareholders   15,184 12,856 118.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SANOFI INDIA With:   FRESENIUS KABI ONCO.  DIVIS LABORATORIES  FULFORD INDIA  ALEMBIC PHARMA  AJANTA PHARMA  

Compare SANOFI INDIA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Global Stock Markets Rebound After Sharp Weekly Drop(RoundUp)

Global financial markets rallied this week and brushed aside a rise in global borrowing costs while the dollar hit its lowest level since 2014.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Here's What You Should Do in this Market Crash(The 5 Minute Wrapup)

Feb 6, 2018

The market correction has provided a golden opportunity to buy five high-quality safe stocks.

As the Market Corrects... It's Time to Buy More(Smart Contrarian)

Feb 5, 2018

The recent sell off in the stock market offers buying opportunity in some quality small caps.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

When Small is Not Always Beautiful(Chart Of The Day)

Feb 6, 2018

Big companies enjoying tax deductions and exemptions have an edge over the small companies.

What Should Mutual Fund Investors Do After LTCG Tax Norms(Outside View)

Feb 6, 2018

PersonalFN explain what investors should after LTCG tax norms.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SANOFI INDIA SHARE PRICE


Feb 16, 2018 (Close)

TRACK SANOFI INDIA

  • Track your investment in SANOFI INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SANOFI INDIA 8-QTR ANALYSIS

COMPARE SANOFI INDIA WITH

MARKET STATS